FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281979063> ?p ?o ?g. }

• W4281979063 endingPage "9527" @default.
• W4281979063 startingPage "9527" @default.
• W4281979063 abstract "9527 Background: Combination of immune checkpoint inhibitors and targeted therapy may produce durable and deep response in a higher proportion of pts with BRAF V600–mutant unresectable or metastatic melanoma. A recent report from the randomized, double-blind, placebo (PBO)-controlled Part 3 of the Phase 3 COMBI-i trial (NCT02967692) failed to show a statistically significant progression-free survival (PFS) benefit (hazard ratio (HR) of 0.82 (95% CI, 0.66‒1.03, p=.042)). Here, we report 3-year OS data from COMBI-i part 3. Methods: Eligible pts were randomized 1:1 to receive either S+D+T (n = 267; S 400 mg IV Q4W + D 150 mg orally BID + T 2 mg orally QD) or PBO+D+T (n = 265), until progression or unacceptable toxicity. Although the primary endpoint of PFS was not met, exploratory OS and safety analyses were performed. OS was summarized descriptively using Kaplan–Meier methods and HR was estimated using a stratified cox regression model. Results: As of October 19, 2021 (median follow-up, 42.8 months), the median OS was not reached in S+D+T arm and was 40.4 months with PBO+D+T (HR 0.796; 95% CI, 0.615‒1.029). There were 113 (42.3%) deaths in the S+D+T and 126 (47.5%) in the PBO+D+T. Estimated 2-year and 3-year OS rates were 67.7% (95% CI 61.6‒73.1) and 60.1% (95% CI 53.8‒65.8) with S+D+T vs 61.9% (95% CI 55.6‒67.5) and 52.9% (95% CI 46.6‒58.9) with PBO+D+T, respectively. An OS benefit was observed with S+D+T in these prespecified subgroups – Eastern Cooperative Oncology Group Performance Status (ECOG PS) 1 (HR 0.50; 95% CI, 0.32‒0.8), age ≥65 years (HR 0.58; 95% CI, 0.36‒0.94), PD-L1 negative ( < 1%) (HR 0.62; 95% CI, 0.42‒0.91), sum of lesion diameters ≥ 66 mm at baseline (HR 0.63; 95% CI, 0.43‒0.91) and metastatic sites ≥ 3 (HR 0.66; 95% CI, 0.47‒0.94). Adverse events (AEs) irrespective of study treatment relationship were observed in 99.3% of pts in S+D+T vs 97.3% in PBO+D+T. The most common AEs (in > 30%; all grades) were pyrexia, diarrhea, and nausea. Grade ≥3 treatment-related AEs (TRAEs) occurred in 56.9% vs 35.2% of pts treated with S+D+T vs PBO+D+T, respectively. Dose reductions of D and T due to AEs were more frequent in the S+D+T arm than PBO+D+T arm (47.2% vs 25.4% and 45.7% vs 25.4%, respectively), contributing to a lower relative dose intensity; the TRAEs leading to discontinuation of all 3 study drugs occurred in 13.5% vs 8% of pts, respectively. Conclusions: Results from this landmark 3-year OS analysis from COMBI-i- part 3 was consistent with the primary analysis, while the PBO+D+T showed a higher OS rate than previously observed for D+T alone in COMBI D/V studies, with a longer median follow-up. Subgroup analyses showed that ECOG PS 1, age ≥65 years, negative PD-L1 status and high tumor burden were associated with better OS in S+D+T in terms of HR. Clinical trial information: NCT02967692." @default.
• W4281979063 created "2022-06-13" @default.
• W4281979063 creator A5010492722 @default.
• W4281979063 creator A5022585118 @default.
• W4281979063 creator A5023174631 @default.
• W4281979063 creator A5029398339 @default.
• W4281979063 creator A5033928550 @default.
• W4281979063 creator A5034365278 @default.
• W4281979063 creator A5045165774 @default.
• W4281979063 creator A5061072132 @default.
• W4281979063 creator A5063245135 @default.
• W4281979063 creator A5064875028 @default.
• W4281979063 creator A5066493892 @default.
• W4281979063 creator A5067794998 @default.
• W4281979063 creator A5069095893 @default.
• W4281979063 creator A5070576000 @default.
• W4281979063 creator A5070733775 @default.
• W4281979063 creator A5071263994 @default.
• W4281979063 creator A5073146875 @default.
• W4281979063 creator A5083745558 @default.
• W4281979063 creator A5085499539 @default.
• W4281979063 creator A5090633646 @default.
• W4281979063 date "2022-06-01" @default.
• W4281979063 modified "2023-10-15" @default.
• W4281979063 title "Dabrafenib (D) and trametinib (T) plus spartalizumab (S) in patients (pts) with previously untreated <i>BRAF</i> V600–mutant unresectable or metastatic melanoma: Three-year overall survival (OS) data from the randomized part 3 of the phase III COMBI-i trial." @default.
• W4281979063 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.9527" @default.
• W4281979063 hasPublicationYear "2022" @default.
• W4281979063 type Work @default.
• W4281979063 citedByCount "2" @default.
• W4281979063 countsByYear W42819790632022 @default.
• W4281979063 countsByYear W42819790632023 @default.
• W4281979063 crossrefType "journal-article" @default.
• W4281979063 hasAuthorship W4281979063A5010492722 @default.
• W4281979063 hasAuthorship W4281979063A5022585118 @default.
• W4281979063 hasAuthorship W4281979063A5023174631 @default.
• W4281979063 hasAuthorship W4281979063A5029398339 @default.
• W4281979063 hasAuthorship W4281979063A5033928550 @default.
• W4281979063 hasAuthorship W4281979063A5034365278 @default.
• W4281979063 hasAuthorship W4281979063A5045165774 @default.
• W4281979063 hasAuthorship W4281979063A5061072132 @default.
• W4281979063 hasAuthorship W4281979063A5063245135 @default.
• W4281979063 hasAuthorship W4281979063A5064875028 @default.
• W4281979063 hasAuthorship W4281979063A5066493892 @default.
• W4281979063 hasAuthorship W4281979063A5067794998 @default.
• W4281979063 hasAuthorship W4281979063A5069095893 @default.
• W4281979063 hasAuthorship W4281979063A5070576000 @default.
• W4281979063 hasAuthorship W4281979063A5070733775 @default.
• W4281979063 hasAuthorship W4281979063A5071263994 @default.
• W4281979063 hasAuthorship W4281979063A5073146875 @default.
• W4281979063 hasAuthorship W4281979063A5083745558 @default.
• W4281979063 hasAuthorship W4281979063A5085499539 @default.
• W4281979063 hasAuthorship W4281979063A5090633646 @default.
• W4281979063 hasConcept C121608353 @default.
• W4281979063 hasConcept C126322002 @default.
• W4281979063 hasConcept C143998085 @default.
• W4281979063 hasConcept C168563851 @default.
• W4281979063 hasConcept C184235292 @default.
• W4281979063 hasConcept C203092338 @default.
• W4281979063 hasConcept C207103383 @default.
• W4281979063 hasConcept C2776131300 @default.
• W4281979063 hasConcept C2777658100 @default.
• W4281979063 hasConcept C2778472372 @default.
• W4281979063 hasConcept C2778715236 @default.
• W4281979063 hasConcept C2778830669 @default.
• W4281979063 hasConcept C2780739268 @default.
• W4281979063 hasConcept C2994587330 @default.
• W4281979063 hasConcept C3019894029 @default.
• W4281979063 hasConcept C44249647 @default.
• W4281979063 hasConcept C502942594 @default.
• W4281979063 hasConcept C50382708 @default.
• W4281979063 hasConcept C57074206 @default.
• W4281979063 hasConcept C71924100 @default.
• W4281979063 hasConcept C86803240 @default.
• W4281979063 hasConcept C90924648 @default.
• W4281979063 hasConcept C95444343 @default.
• W4281979063 hasConceptScore W4281979063C121608353 @default.
• W4281979063 hasConceptScore W4281979063C126322002 @default.
• W4281979063 hasConceptScore W4281979063C143998085 @default.
• W4281979063 hasConceptScore W4281979063C168563851 @default.
• W4281979063 hasConceptScore W4281979063C184235292 @default.
• W4281979063 hasConceptScore W4281979063C203092338 @default.
• W4281979063 hasConceptScore W4281979063C207103383 @default.
• W4281979063 hasConceptScore W4281979063C2776131300 @default.
• W4281979063 hasConceptScore W4281979063C2777658100 @default.
• W4281979063 hasConceptScore W4281979063C2778472372 @default.
• W4281979063 hasConceptScore W4281979063C2778715236 @default.
• W4281979063 hasConceptScore W4281979063C2778830669 @default.
• W4281979063 hasConceptScore W4281979063C2780739268 @default.
• W4281979063 hasConceptScore W4281979063C2994587330 @default.
• W4281979063 hasConceptScore W4281979063C3019894029 @default.
• W4281979063 hasConceptScore W4281979063C44249647 @default.
• W4281979063 hasConceptScore W4281979063C502942594 @default.
• W4281979063 hasConceptScore W4281979063C50382708 @default.
• W4281979063 hasConceptScore W4281979063C57074206 @default.
• W4281979063 hasConceptScore W4281979063C71924100 @default.
• W4281979063 hasConceptScore W4281979063C86803240 @default.
• W4281979063 hasConceptScore W4281979063C90924648 @default.
• W4281979063 hasConceptScore W4281979063C95444343 @default.

• next